Patents by Inventor Liguang Chen

Liguang Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER TREATMENT COMBINATIONS
    Publication number: 20240115700
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Application
    Filed: March 30, 2023
    Publication date: April 11, 2024
    Inventors: Thomas J. KIPPS, Liguang CHEN, Bing CUI
  • Cancer treatment combinations
    Patent number: 11654193
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 23, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20230110249
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: March 16, 2022
    Publication date: April 13, 2023
    Inventors: Thomas James KIPPS, Jian YU, Bing CUI, Liguang CHEN, George F. WIDHOPF, Charles PRUSSAK
  • Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
    Patent number: 11312787
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: April 26, 2022
    Assignee: The Regents of the University of California
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • CANCER TREATMENT COMBINATIONS
    Publication number: 20210038716
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Application
    Filed: May 8, 2020
    Publication date: February 11, 2021
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • Cancer treatment combinations
    Patent number: 10688181
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 23, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20190389962
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: May 14, 2019
    Publication date: December 26, 2019
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
    Patent number: 10344096
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: July 9, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20180066063
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: June 9, 2017
    Publication date: March 8, 2018
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • CANCER TREATMENT COMBINATIONS
    Publication number: 20170368173
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Application
    Filed: June 27, 2017
    Publication date: December 28, 2017
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
    Patent number: 9758591
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 12, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20150232569
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 20, 2015
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George Widhopf, Charles Prussak
  • Methods and compounds for lymphoma cell detection and isolation
    Patent number: 8212009
    Abstract: Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: July 3, 2012
    Assignee: The Regents of the University of California
    Inventors: Thomas J. Kipps, Tetsuya Fukuda, Tomoyuki Endo, Suping Zhang, Liguang Chen, H. Elizabeth Broome
  • Methods and Compounds for Lymphoma Cell Detection and Isolation
    Publication number: 20100062005
    Abstract: Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.
    Type: Application
    Filed: August 21, 2009
    Publication date: March 11, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Tetsuya Fukuda, Tomoyuki Endo, Suping Zhang, Liguang Chen, H. Elizabeth Broome